References
- Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology. Internet 2002;59(9 Suppl 5):S21-6. Available from: www.ncbi.nlm.nih.gov/pubmed/12428028
- Shinnar S, Berg AT, O’Dell C, et al. Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Ann. Neurol. Internet 2000;48(2):122-3. Available from: www.ncbi.nlm.nih.gov/pubmed/11261451
- McDonald BC, Flashman LA, Saykin AJ. Executive dysfunction following traumatic brain injury: neural substrates and treatment strategies. NeuroRehabilitation 2002;17(4):333-44
- Studer M, Boltshauser E, Mori AC, et al. Factors affecting cognitive outcome in early pediatric stroke. Neurology 2014;82(9):784-92
- Friedman A, Kaufer D, Heinemann U. Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. Epilepsy Res Internet 2009;85(2-3):142-9. Available from: www.ncbi.nlm.nih.gov/pubmed/19362806
- Abbott NJ, Friedman A. Overview and introduction: the blood-brain barrier in health and disease. Epilepsia Internet 2012;53(Suppl 6):1-6. Available from: www.ncbi.nlm.nih.gov/pubmed/23134489
- Abbott NJ, Patabendige AAK, Dolman DEM, et al. Structure and function of the blood-brain barrier. Neurobiol Dis Internet 2010;37(1):13-25. Available from: www.ncbi.nlm.nih.gov/pubmed/19664713
- Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci Internet 2006;7(1):41-53. Available from: www.ncbi.nlm.nih.gov/pubmed/16371949
- Neuwelt EA. Mechanisms of Disease: The Blood-Brain Barrier. Neurosurgery Internet 2004;54(1):131-42. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006123-200401000-00017
- Oby E, Janigro D. The blood-brain barrier and epilepsy. Epilepsia Internet 2006;47(11):1761-74. Available from: www.ncbi.nlm.nih.gov/pubmed/17116015
- Tomkins O, Kaufer D, Korn A, et al. Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol Internet 2001;21(6):675-91. Available from: www.ncbi.nlm.nih.gov/pubmed/12043841
- Van Vliet EA, da Costa Araújo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain Internet 2007;130(Pt 2):521-34. Available from: www.ncbi.nlm.nih.gov/pubmed/17124188
- Marchi N, Angelov L, Masaryk T, et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007;48(4):732-42
- Tomkins O, Friedman O, Ivens S, et al. Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol Dis Internet 2007;25(2):367-77. Available from: www.ncbi.nlm.nih.gov/pubmed/17188501
- Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain A J Neurol Internet 2007;130(Pt 2):535-47. Available from: www.ncbi.nlm.nih.gov/pubmed/17121744
- Seiffert E, Dreier JP, Ivens S, et al. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci Internet 2004;24(36):7829-36. Available from: www.ncbi.nlm.nih.gov/pubmed/15356194
- Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J Neurosci Internet 2009;29(28):8927-35. Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2875073&tool=pmcentrez&rendertype=abstract
- Bar-Klein G, Cacheaux LP, Kamintsky L, et al. Losartan prevents acquired epilepsy via TGF-β signaling suppression. Ann Neurol Internet 2014;75(6):864-75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24659129
- David Y, Cacheaux LP, Ivens S, et al. Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis? J Neurosci Internet 2009;29(34):10588-99. Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2875068&tool=pmcentrez&rendertype=abstract
- Lapilover EG, Lippmann K, Salar S, et al. Peri-infarct blood-brain barrier dysfunction facilitates induction of spreading depolarization associated with epileptiform discharges. Neurobiol Dis Internet 2012;48(3):495-506. Available from: www.ncbi.nlm.nih.gov/pubmed/22782081
- Frigerio F, Frasca A, Weissberg I, et al. Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. Epilepsia 2012;53(11):1887-97
- OECD. Mortality from heart disease and stroke, in Health at a Glance: Europe 2012. OECD Publishing, Paris, France, 2012
- Pitkänen A, Kemppainen S, Ndode-Ekane XE, et al. Posttraumatic epilepsy - Disease or comorbidity? Epilepsy Behav Internet 2014; Available from: www.ncbi.nlm.nih.gov/pubmed/24529830
- Health statistics and information systems: global health estimates. World Heal Organ Internet 2011; Available from: www.who.int/healthinfo/global_burden_disease/en/
- Langlois JA, Rutland-Brown W, Wald MM. The Epidemiology and Impact of Traumatic Brain Injury. J Head Trauma Rehabil 2006;21(5):375-8
- Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol Internet 2010;6(7):393-403. Available from: www.ncbi.nlm.nih.gov/pubmed/20551947
- Patel HC, Bouamra O, Woodford M, et al. Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study. Lancet 2005;366(9496):1538-44
- Suarez JI, Zaidat OO, Suri MF, et al. Length of stay and mortality in neurocritically ill patients: impact of a specialized neurocritical care team. Crit Care Med 2004;32(11):2311-17
- Tepas JJ, Pracht EE, Orban BL, Flint LM. High-volume trauma centers have better outcomes treating traumatic brain injury. J. Trauma Acute Care Surg 2013;74(1):143-7
- Neuhaus AA, Rabie T, Sutherland BA, et al. Importance of Preclinical Research in the Development of Neuroprotective Strategies for Ischemic Stroke. JAMA Neurol Internet 2014;71(5):634-9. Available from: www.ncbi.nlm.nih.gov/pubmed/24590416
- McConeghy K, Hatton J, Hughes L, Cook A. A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury. CNS Drugs Internet 2012;26(7):613-36. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=ovftm&NEWS=N&AN=00023210-201226070-00007
- Ghajar J. Traumatic brain injury. Lancet 2000;356(9233):923-9
- Brain trauma foundation, American Association of Neurologcal Surgeons (AANS), Congress of Neurological Surgeons (CNS) AJS on N and CC. guidelines for the management of severe traumatic brain injury, 3rd edition. J Neurotrauma 2007;24:S1-S106
- Maas AIR, Marmarou A, Murray GD, et al. Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. J Neurotrauma 2007;24(2):232-8
- Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma 2002;19(5):503-57
- Rosenfeld J V, Maas AI, Bragge P, et al. Early management of severe traumatic brain injury. Lancet 2012;380(9847):1088-98
- Jiang JY, Gao GY, Li WP, et al. Early indicators of prognosis in 846 cases of severe traumatic brain injury. J Neurotrauma 2002;19(7):869-74
- Zlokovic B V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57(2):178-201
- Ruttan L, Martin K, Liu A, et al. Long-term cognitive outcome in moderate to severe traumatic brain injury: a meta-analysis examining timed and untimed tests at 1 and 4.5 or more years after injury. Arch Phys Med Rehabil 2008;89(12 Suppl):S69-76
- Annegers JF, Hauser WA, Coan SP, Rocca WA. A population-based study of seizures after traumatic brain injuries. N Engl J Med 1998;338(1):20-4
- Heinemann U, Kaufer D, Friedman A. Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy. Glia Internet 2012;60(8):1251-7. Available from: www.ncbi.nlm.nih.gov/pubmed/22378298
- Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13(2):204-10
- Lavoie P, Robitaille G, Agharazii M, et al. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 2005;23(10):1895-903
- Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation Internet 2001;103(6):789-91. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/01.CIR.103.6.789
- Li Z, Bains JS, Ferguson A V. Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res Bull 1993;30(1-2):33-9
- Wang JM, Tan J, Leenen FHH. Central nervous system blockade by peripheral administration of AT1 receptor blockers. J Cardiovasc Pharmacol 2003;41(4):593-9
- Polidori C, Ciccocioppo R, Nisato D, et al. Evaluation of the ability of irbesartan to cross the blood–brain barrier following acute intragastric treatment. Eur J Pharmacol Internet 1998;352(1):15-21. Available from: www.sciencedirect.com/science/article/pii/S001429999800329X
- Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev Internet 2013;65(2):809-48. Available from: www.ncbi.nlm.nih.gov/pubmed/23487168
- Temkin NR. Risk factors for posttraumatic seizures in adults. Epilepsia 2003;44(Suppl 10):18-20
- Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia 2003;44(Suppl 1):11-17
- Lee ST, Lui TN. Early seizures after mild closed head injury. J Neurosurg 1992;76(3):435-9
- Annegers JF, Grabow JD, Groover R V, et al. Seizures after head trauma: a population study. Neurology 1980;30(7 Pt 1):683-9
- Christensen J, Pedersen MG, Pedersen CB, et al. Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study. Lancet 2009;373(9669):1105-10
- Englander J, Bushnik T, Duong TT, et al. Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. Arch Phys Med Rehabil 2003;84(3 Suppl 1):365-373
- Ferguson PL, Smith GM, Wannamaker BB, et al. A population-based study of risk of epilepsy after hospitalization for traumatic brain injury. Epilepsia 2010;51(5):891-8
- Raymont V, Salazar AM, Lipsky R, et al. Correlates of posttraumatic epilepsy 35 years following combat brain injury. Neurology 2010;75(3):224-9
- Pagni CA, Zenga F. Posttraumatic epilepsy with special emphasis on prophylaxis and prevention. Acta Neurochir 2005;93:27-34
- Yeh CC, Chen TL, Hu CJ, et al. Risk of epilepsy after traumatic brain injury: a retrospective population-based cohort study. J Neurol Neurosurg Psychiatry 2013;84(4):441-5
- Zheng Z, Shi H, Jia J, et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011;12(3):365-74
- Banati RB. Visualising microglial activation in vivo. Glia 2002;40(2):206-17
- Butler T, Ichise M, Teich AF, et al. Imaging Inflammation in a Patient with Epilepsy Due to Focal Cortical Dysplasia. J Neuroimaging 2013;23(1):129-31
- Kumar A, Ajilore O, Kepe V, et al. Mood, cognition and in vivo protein imaging: the emerging nexus in clinical neuroscience. Int J Geriatr Psychiatry 2008;23(6):555-63
- Rissanen E, Tuisku J, Rokka J, et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195. J Nucl Med Internet 2014;55(6):939-44. Available from: http://jnm.snmjournals.org/content/55/6/939.abstract
- Hammen T, Hildebrandt M, Stadlbauer A, et al. Non-invasive detection of hippocampal sclerosis: correlation between metabolite alterations detected by 1H-MRS and neuropathology. NMR Biomed 2008;21(6):545-52
- Mizuno K, Wakai M, Takeda A, Sobue G. Medial temporal atrophy and memory impairment in early stage of Alzheimer’s disease: an MRI volumetric and memory assessment study. J Neurol Sci 2000;173(1):18-24
- Türkdogan-Sözüer D, Ozek MM, Sav A, et al. Serial MRI and MRS studies with unusual findings in Rasmussen’s encephalitis. Eur Radiol 2000;10(6):962-6
- Tomkins O, Feintuch A, Benifla M, et al. Blood-brain barrier breakdown following traumatic brain injury: a possible role in posttraumatic epilepsy. Cardiovasc Psychiatry Neurol 2011;2011:765923
- Chassidim Y, Veksler R, Lublinsky S, et al. Quantitative imaging assessment of blood-brain barrier permeability in humans. Fluids Barriers CNS Internet 2013;10(1):9 Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3570379&tool=pmcentrez&rendertype=abstract
- Aronica E, Crino PB. Inflammation in epilepsy: clinical observations. Epilepsia 2011;52(Suppl 3):26-32
- Cekanaviciute E, Fathali N, Doyle KP, et al. Astrocytic transforming growth factor-beta signaling reduces subacute neuroinflammation after stroke in mice. Glia 2014;62(8):1227-40
- Kuruvilla AP, Shah R, Hochwald GM, et al. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991;88(7):2918-21
- Prehn JH, Backhauss C, Krieglstein J. Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J Cereb Blood Flow Metab 1993;13(3):521-5
- Armstead WM, Mirro R, Zuckerman SL, et al. Transforming growth factor-beta attenuates ischemia-induced alterations in cerebrovascular responses. Am J Physiol 1993;264(2 Pt 2):H381-5
- Harris-White ME, Chu T, Balverde Z, et al. Effects of transforming growth factor-beta (isoforms 1-3) on amyloid-beta deposition, inflammation, and cell targeting in organotypic hippocampal slice cultures. J Neurosci 1998;18(24):10366-74
- Logan A, Green J, Hunter A, et al. Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta2. Eur J Neurosci 1999;11(7):2367-74
- Sun J, Liu S, Lin Y, et al. TGF-β promotes glioma cell growth via activating Nodal expression through Smad and ERK1/2 pathways. Biochem Biophys Res Commun Internet 2014;443(3):1066-72. Available from: www.sciencedirect.com/science/article/pii/S0006291X13021682
- Villapol S, Wang Y, Adams M, Symes AJ. Smad3 deficiency increases cortical and hippocampal neuronal loss following traumatic brain injury. Exp Neurol Internet 2013;250:353-65. Available from: www.sciencedirect.com/science/article/pii/S0014488613003117
- Wang Y, Moges H, Bharucha Y, Symes A. Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex. Exp Neurol 2007;203(1):168-84
- Botfield H, Gonzalez AM, Abdullah O, et al. Decorin prevents the development of juvenile communicating hydrocephalus. Brain 2013;136(9):2842-58
- Manaenko A, Lekic T, Barnhart M, et al. Inhibition of transforming growth factor-β attenuates brain injury and neurological deficits in a rat model of germinal matrix hemorrhage. Stroke 2014;45(3):828-34
- Bull ND, Johnson T V, Welsapar G, et al. Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Invest Ophthalmol Vis Sci 2011;52(6):3309-20
- Wang J, Pang T, Hafko R, et al. Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation. Neuropharmacology Internet 2014;79:249-61. Available from: www.sciencedirect.com/science/article/pii/S0028390813005686
- Ongali B, Nicolakakis N, Tong X, et al. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model. Neurobiol Dis Internet 2014;68:126-36. Available from: http://dx.doi.org/10.1016/j.nbd.2014.04.018
- Sabharwal R, Chapleau MW. Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin angiotensin system. Exp Physiol Internet 2014;99(4):627-31. Available from: www.ncbi.nlm.nih.gov/pubmed/24334334
- Marvar PJ, Goodman J, Fuchs S, et al. Angiotensin Type 1 Receptor Inhibition Enhances the Extinction of Fear Memory. Biol Psychiatry 2014;75(11):864-72
- Min LJ, Mogi M, Shudou M, et al. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension Internet 2012;59(5):1079-88. Available from: www.ncbi.nlm.nih.gov/pubmed/22454480
- Palkovits M, Šebekov K, Klenovics KS, et al. Neuronal Activation in the Central Nervous System of Rats in the Initial Stage of Chronic Kidney Disease-Modulatory Effects of Losartan and Moxonidine. PLoS One 2013;8(6):e66543
- Zhang TL, Fu JL, Geng Z, et al. The Neuroprotective Effect of Losartan through Inhibiting AT1/ASK1/MKK4/JNK3 Pathway Following Cerebral I/R in Rat Hippocampal CA1 Region. CNS Neurosci Ther 2012;18(12):981-7
- Vargas R, Rincón J, Pedreañez A, et al. Role of angiotensin II in the brain inflammatory events during experimental diabetes in rats. Brain Res 2012;1453:64-76
- Pechlivanova DM, Stoynev AG, Tchekalarova JD. The effects of chronic losartan pretreatment on restraint stress-induced changes in motor activity, nociception and pentylenetetrazol generalized seizures in rats. Folia Med (Plovdiv) Internet 2011;53(2):69-73. Available from: www.degruyter.com/view/j/folmed.2011.53.issue-2/v10153-010-0040-z/v10153-010-0040-z.xml
- Zhu D, Shi J, Zhang Y, et al. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS One 2011;6(1):e16037
- Smeda JS, Daneshtalab N. The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. J Cereb Blood Flow Metab 2011;31(2):476-85
- Smeda JS, McGuire JJ. Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp. Stroke 2007;38(5):1590-6
- Antoniou T, Camacho X, Yao Z, et al. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. CMAJ Internet 2013;185(12):1035-41. Available from: www.ncbi.nlm.nih.gov/pubmed/23836856; http://www.ncbi.nlm.nih.gov/pubmed/23836857
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet Internet 2002;359(9311):995-1003. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673602080893
- Devereux RB, Dahlöf B, Kjeldsen SE, et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the life randomized trial. Ann Intern Med Internet 2003;139(3):169-77. Available from: http://dx.doi.org/10.7326/0003-4819-139-3-200308050-00006
- Kizer JR, Dahlöf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension study. Hypertens Internet 2005;45(1):46-52. Available from: http://hyper.ahajournals.org/content/45/1/46.abstract
- Victor RG. Pathophysiology of target-organ disease: does angiotensin II remain the key? J Clin Hypertens (Greenwich) 2007;9(11 Suppl 4):4-10
- Mochizuki S, Dahlof B, Shimizu M, et al. RETRACTED: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet Internet 2007;369(9571):1431-9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673607606692
- Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol 2004;44(6):1175-80
- Suzuki H, Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005;28(4):307-14